Is Ertugliflozin + Sitagliptin registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 0 valid registrations of Ertugliflozin + Sitagliptin.

Is Ertugliflozin + Sitagliptin approved by the US FDA?

Drugs@FDA lists 1 application product line for Ertugliflozin + Sitagliptin, including STEGLUJAN (Prescription).

Active substances

Ertugliflozin + Sitagliptin

SFDA 2
US FDA 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
Steglujan	100,5 mg,mg	Film-coated tablet · Oral use	30 Blister	SAR 226.05	NCE · Prescription	Merck Sharp & Dohme B.V	Withdrawn by MAH · Not Marketed
Steglujan	100,15 mg,mg	Film-coated tablet · Oral use	30 Blister	SAR 226.05	NCE · Prescription	Merck Sharp & Dohme B.V	Withdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
STEGLUJAN	5MG;EQ 100MG BASE; 15MG;EQ 100MG BASE	tablet · oral	MSD SUB MERCK	Prescription	19 Dec 2017

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.